AE Wealth Management LLC Sells 1,665 Shares of Inogen, Inc (NASDAQ:INGN)

AE Wealth Management LLC reduced its holdings in Inogen, Inc (NASDAQ:INGN) by 9.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,545 shares of the medical technology company’s stock after selling 1,665 shares during the quarter. AE Wealth Management LLC owned about 0.06% of Inogen worth $111,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the business. Ameriprise Financial Inc. raised its stake in shares of Inogen by 0.6% in the fourth quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock valued at $7,785,000 after purchasing an additional 5,148 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in Inogen by 4.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock worth $5,788,000 after buying an additional 28,517 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after purchasing an additional 123,208 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Inogen by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 492,900 shares of the medical technology company’s stock valued at $4,520,000 after acquiring an additional 75,000 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Inogen by 16.8% during the fourth quarter. Federated Hermes Inc. now owns 404,273 shares of the medical technology company’s stock worth $3,707,000 after buying an additional 58,257 shares during the last quarter. 89.94% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on INGN shares. B. Riley initiated coverage on Inogen in a report on Monday, June 16th. They set a “buy” rating and a $14.00 target price on the stock. Needham & Company LLC raised shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 price target for the company in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus dropped their target price on Inogen from $10.00 to $7.00 and set a “hold” rating on the stock in a report on Thursday, May 8th.

Inogen Trading Down 1.6%

INGN stock opened at $6.21 on Friday. The business’s 50 day simple moving average is $6.71 and its 200 day simple moving average is $7.75. Inogen, Inc has a 1-year low of $5.70 and a 1-year high of $13.33. The firm has a market capitalization of $166.99 million, a PE ratio of -5.40 and a beta of 1.72.

Inogen (NASDAQ:INGN) last announced its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.27. The company had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. As a group, sell-side analysts predict that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.